Agility with Complex Data Sets – Integration of Predicted and Empirical Data for Rapid Innovation in Drug Discovery
Thursday, December 5, 2024 at 8 AM (PT) | 11 AM (ET)
Reserve Your Webinar SeatJoin leading experts for an examination of modern approaches to integrating computational predictions with experimental data in protein drug discovery. As the volume and complexity of both predicted and empirical data continue to grow, the ability to effectively harmonize these diverse data streams becomes crucial for accelerating therapeutic development. This webinar will explore cutting-edge methods for managing, analyzing, and acting on complex scientific datasets.
The session will explore novel methodologies for integrating diverse data types in drug discovery pipelines. We will discuss approaches to harmonizing heterogeneous data streams—including molecular dynamics simulations, binding affinity predictions, and experimental validation data.
This 45 minute discussion will be followed by 15 minutes of live Q&A with the speakers.
Key Learning Objectives
-
Understanding approaches to streamlining the integration of chemistry, biology, and computational data streams in modern drug discovery with knowledge bases such as Congruence’s Revenir™
-
Methods for optimizing resource allocation and prioritization between computational predictions and experimental validation
-
Novel approaches to harmonizing diverse data sources for identification of therapeutic opportunities
-
Applications of generative AI models in designing for novel targets and binding pockets
Lee Fader, PhD
VP of Chemistry at Congruence
Lee Fader is the Vice President of Chemistry at Congruence Therapeutics, specializing in small molecule drug discovery and development. Previously, he held leadership positions at Ventus Therapeutics and Inception Sciences, where he advanced early-stage therapeutic programs. His industry experience includes significant contributions at Vertex Pharmaceuticals and an extended tenure at Boehringer Ingelheim, where he progressed from Research Scientist to Principal Scientist. Lee holds a PhD from McGill University under the supervision of Dr. Youla Tsantrizos and a Bachelor of Science degree from Concordia University.
Jeremy Dupaul-Chicoine, PhD
Associate Director of Biology at Congruence
Jeremy Dupaul-Chicoine Ph.D., is a biologist with close to 10 years of experience in drug discovery. Currently serving as an Associate Director of Biology at Congruence Therapeutics where he is the biology lead for the GBA1 Allosteric Modulator Program. Previously, he held various scientific roles at EnGene Inc and was involved in the preclinical research of Detalimogene. Jeremy holds a Ph.D. from McGill University.
Maximilian Ebert, PhD
Executive Director, Computational Chemistry at Congruence
Maximilian Ebert is the Executive Director of the Computational Chemistry Group at Congruence Therapeutics, specializing in molecular dynamics and free energy calculations. Previously, he was instrumental in advancing the Molecular Operating Environment (MOE) platform at Chemical Computing Group, contributing both novel applications and business development strategies. Maximilian holds a PhD in biochemistry from the University of Montreal, with a focus on biocatalysis and enzyme design, and a master’s degree in chemical engineering from the University of Dortmund, Germany.